Cargando…
Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials
Heart failure with preserved ejection fraction (HFpEF) is a disease with limited evidence-based treatment options. Mineralocorticoid receptor antagonists (MRA) offer benefit in heart failure with reduced ejection fraction (HFrEF), but their impact in HFpEF remains unclear. We therefore evaluated the...
Autores principales: | Kapelios, Chris J., Murrow, Jonathan R., Nührenberg, Thomas G., Montoro Lopez, Maria N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477010/ https://www.ncbi.nlm.nih.gov/pubmed/30618017 http://dx.doi.org/10.1007/s10741-018-9758-0 |
Ejemplares similares
-
Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction
por: Suzuki, Sho, et al.
Publicado: (2020) -
Implication of Mineralocorticoid Receptor Antagonist Esaxerenone in Patients With Heart Failure With Preserved Ejection Fraction
por: Imamura, Teruhiko, et al.
Publicado: (2021) -
Effects of Mineralocorticoid Receptor Antagonists in Early-Stage Heart Failure With Preserved Ejection Fraction
por: Kagami, Kazuki, et al.
Publicado: (2023) -
The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
por: Kintscher, Ulrich, et al.
Publicado: (2023) -
Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction
por: Serenelli, Matteo, et al.
Publicado: (2020)